All In Biotech

Drug Trial Radar · NCT06707103

Tissue Repair Gel in Venous Leg Ulcers in AU/US

A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)

Last checked: Nov 20, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

312

Planned (sponsor's estimate)

Start

Apr 2025

Primary completion

Dec 2026

Study completion Feb 2027

Sponsor

Lead sponsor
TR TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.

Conditions

  • Venous Leg Ulcer
  • Venous Ulcer
  • Venous Stasis Ulcer
  • Venous Stasis
  • Wound Heal
  • Wound
  • Venous Insufficiency of Leg
  • Non-healing Wound

Interventions

  • TR987 0.1% gel + Standard of CareDrug

    6mg topical gel for application plus Standard of Care (wound cleansing/dressings and compression bandaging)

  • Standard of careOther

    Standard of Care (wound cleansing/dressings and compression bandaging)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with Complete Closure of the target ulcer at or before the Week-16 end of treatment (EOT) visit.Time frame: 16 weeks

Locations

12 sites in 2 countries. Site status is shown where the registry gives one.

  • Clincial Research Site 92

    Jacksonville, Florida · Recruiting

  • Clincial Research Site 77

    Clinton Twp, Michigan · Recruiting

  • Clincial Research Site 82

    Lake Success, New York · Not yet recruiting

  • Clinical Research Site 76

    Fort Worth, Texas · Recruiting

  • Clincial Research Site 62

    Camperdown, New South Wales, Australia · Not yet recruiting

  • Clinical Research Site 84

    Kogarah, New South Wales, Australia · Not yet recruiting

  • Clincial Research Site 78

    Orange, New South Wales, Australia · Not yet recruiting

  • Clincial Research Site 85

    Sydney, New South Wales, Australia · Not yet recruiting

  • Clincial Research Site 74

    Bendigo, Victoria, Australia · Not yet recruiting

  • Clincial Research Site 60

    Ivanhoe, Victoria, Australia · Recruiting

  • Clincial Research Site 65

    Shepparton, Victoria, Australia · Recruiting

  • Clincial Research Site 75

    Nedlands, Western Australia, Australia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.